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The high incidence of aneuploidy in the embryo is considered the principal cause for low
human fecundity. However, the prevalence of aneuploidy dramatically declines as pregnancy
progresses, with the steepest drop occurring as the embryo completes implantation. Despite
the fact that the plasticity of the embryo in dealing with aneuploidy is fundamental to normal
development, the mechanisms responsible for eliminating aneuploid cells are unclear. Here,
using a mouse model of chromosome mosaicism, we show that aneuploid cells are pre-
ferentially eliminated from the embryonic lineage in a p53-dependent process involving both
autophagy and apoptosis before, during and after implantation. Moreover, we show that
diploid cells in mosaic embryos undertake compensatory proliferation during the implantation
stages to confer embryonic viability. Together, our results indicate a close link between
aneuploidy, autophagy, and apoptosis to refine the embryonic cell population and ensure only
chromosomally fit cells proceed through development of the fetus.
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Humans exhibit relatively suboptimal fertility compared toother mammals1. Studies of early pregnancy loss indicatethat only 30% of conceptions progress to live birth2.
Cytogenetic studies of spontaneous abortions and pre-implan-
tation in vitro fertilised (IVF) embryos show that most of these
losses are associated with aneuploidy2–4. Interestingly, both
normal fertilisation and IVF often give rise to embryos that are
mosaics, i.e. contain cells with different chromosome constitu-
tions5–7. Although ~60% of pre-implantation IVF embryos
exhibit diploid–aneuploid mosaicism5, our understanding of the
embryo’s ability to cope with such abnormalities is very limited.
The incidence of aneuploidy declines at later stages of develop-
ment, from 73% in pre-implantation stages to only 0.6% in live
births5,8. This reduced frequency of aneuploid cells during
embryonic development could arise via the preferential allocation
of abnormal cells to extra-embryonic lineages9,10, the self-
correction of abnormalities11 or clonal depletion12,13. However,
there is insufficient evidence to support any of these processes in
human embryo development.
We recently established a mouse model of chromosome
mosaicism14 by acutely inhibiting the spindle assembly check-
point (SAC)15. This model allowed us to discover that aneuploid
cells induce different responses in different lineages as the
diploid–aneuploid mosaic embryo develops into the blastocyst14:
apoptosis in the inner cell mass (ICM), which will generate the
embryonic lineage and cell cycle delay in the trophectoderm (TE),
which will form the placenta. However, we also found that more
than half of aneuploid cells still remain by the time of implan-
tation14. Whether these aneuploid cells become eliminated after
implantation, and if so, when and how this elimination takes
place and whether this aneuploid cell elimination affects sur-
rounding diploid cells has remained unknown. We now wish to
address these questions.
Here, we examine the fate of aneuploid cells during implan-
tation and early post-implantation development when the cells of
the embryonic lineage initiate for the first time extensive pro-
liferation and reorganisation in shape, gene expression, epigenetic
signatures and metabolism, laying down the foundation of the
developing body. The results we present here demonstrate that
aneuploid cells are eliminated from the embryonic lineage by
apoptosis, due to proteotoxic stress which in turn activates
autophagy, favouring survival of a diploid embryonic cell pool.
Results
Aneuploid cell loss in the peri/post-implantation epiblast. We
previously showed that aneuploid cells begin to disappear from
the embryonic lineage of the aneuploid mosaic embryos during
pre-implantation development, specifically at the blastocyst
stage14. However, the mechanisms by which aneuploid cells are
eliminated and whether aneuploid cells elimination continues as
embryos implant have remained unknown. To address these
questions, we induced chromosome segregation errors by treating
embryos with a well-established small reversible inhibitor,
reversine, during four- to eight-cell division to inactivate the
SAC15 and confirmed that this treatment significantly increased
the incidence of aneuploidy in comparison to DMSO-treated
controls (Supplementary Fig. 1a–d), in agreement with previous
results14. Thus, we will refer to reversine-treated cells as aneu-
ploid and to control, DMSO-treated cells as diploid throughout
for simplicity.
To recognise diploid and aneuploid cells in mosaic embryos,
we wished to generate chimeras in which diploid and aneuploid
clones could be distinguished from each other. To this end, we
treated non-fluorescent embryos with reversine at the four- to
eight-cell stage division (aneuploid embryo) and membrane-
targeted red fluorescent (mT/mG) embryos with DMSO (diploid
embryo), let embryo develop to the eight-cell stage at which point
we isolated individual cells from each other and aggregated four
red fluorescent diploid and four non-fluorescent aneuploid cells
into the chimeras, and let them develop to the blastocyst stage
(Fig. 1a). We also used the same approach to generate control
diploid–diploid chimeric embryos.
To specifically monitor the fate of the embryonic lineage
beyond the blastocyst stage, we have established an in vitro model
in which the extra-embryonic TE is removed by immunosur-
gery16 and the isolated ICM is embedded in the Matrigel and an
in vitro culture (IVC) implantation medium, which we previously
established17. We showed that this experimental model allows us
to recapitulate the sequential events of implantation and early
post-implantation development: formation of the epiblast rosette
that undergoes lumenogenesis in its centre to form the pro-
amniotic cavity (Supplementary Fig. 2a–c).
In each experiment we generated both aneuploid–diploid and
diploid–diploid chimeric embryos and first cultured them to the
late blastocyst stage and then removed the TE using
immunosurgery, embedded the ICMs in Matrigel and cultured
them in IVC medium for 72 h (Fig. 1a). We found that both
diploid–diploid and the diploid–aneuploid chimeras developed
characteristic post-implantation morphology, in which the
primitive endoderm surrounded the epithelial epiblast that
formed a lumen in its centre (Fig. 1b). The developmental
efficiency of diploid–diploid and diploid–aneuploid chimeras
were similar (Supplementary Fig. 3a, b). The relative proportion
of non-fluorescent cells was significantly lower in the diploid
(red)–aneuploid (non-fluorescent) chimeras than in the diploid
(red)–diploid (non-fluorescent) chimeras both in the epiblast
and the primitive endoderm (Fig. 1c, Supplementary Fig. 3c, d).
Specifically, the frequency of non-fluorescent aneuploid cells in
diploid–aneuploid epiblasts was 30.3% while the frequency of
non-fluorescent diploid cells in diploid–diploid epiblasts was
64.9% (Fig. 1c). A similar preferential depletion of aneuploid
cells was visible in the primitive endoderm, the frequency of
non-fluorescent aneuploid cells in diploid–aneuploid primitive
endoderm was 38.2%, while the frequency of non-fluorescent
diploid cells in diploid–diploid primitive endoderm was 65.9%
(Fig. 1c).
Strikingly, nearly half (47.4%) of epiblasts derived from
diploid–aneuploid chimeras completely lacked non-fluorescent,
aneuploid cells (Supplementary Fig. 3e). In contrast, only 19% of
the diploid–diploid chimeras showed a complete loss of the non-
fluorescent, diploid cells (Supplementary Fig. 3e). Similarly,
31.6% of diploid–aneuploid chimeras lost the non-fluorescent
aneuploid cells in the primitive endoderm, whereas only 10% of
the diploid–diploid chimeric primitive endoderm lacked non-
fluorescent diploid cells (Supplementary Fig. 3f).
We next wanted to determine the fate of aneuploid cells in the
mosaic embryos which were allowed to implant in vivo and in
which TE is not removed. To this end, we treated embryos with
reversine (or DMSO) at the four- to eight-cell stage transition and
generated eight-cell stage diploid–diploid and diploid–aneuploid
chimeras, let them develop to the blastocyst stage, at which point
we transferred embryos to foster mothers (Fig. 1d). We recovered
the chimeric embryos 12 h after implantation and analysed their
composition after 36 h of IVC. We found that the relative
proportion of non-fluorescent cells was significantly lower in the
diploid (red)–aneuploid (non-fluorescent) chimeras than in the
diploid (red)–diploid (non-fluorescent) chimeras in the epiblast
(Fig. 1e, f, Supplementary Fig. 4a, b). Specifically, the frequency of
non-fluorescent aneuploid cells in diploid–aneuploid epiblasts was
19.67% while the frequency of non-fluorescent diploid cells in
diploid–diploid epiblasts was 49.99% (Fig. 1f). The frequency of
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non-fluorescent aneuploid cells in diploid–aneuploid primitive
endoderm was 22.2% while the frequency of non-fluorescent
diploid cells in diploid–diploid primitive endoderm was 34.99%
(Fig. 1f). However, this decrease in the relative proportion of non-
fluorescent cells in the diploid (red)–aneuploid (non-fluorescent)
chimeras than in the diploid (red)–diploid (non-fluorescent)
chimeras was not significant in the primitive endoderm (Supple-
mentary Fig. 4c).
Again, similarly to embryos cultured in vitro, 78.6% of
diploid–aneuploid chimeras contained no non-fluorescent aneu-
ploid cells in the epiblast, whereas only 14.3% of the diploid–diploid
chimeras lacked non-fluorescent diploid cells in the epiblast
(Supplementary Fig. 4d). A similar depletion of aneuploid cells
occurred in the primitive endoderm: 62.5% of diploid–aneuploid
chimeras contained no non-fluorescent aneuploid cells in the
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lacked non-fluorescent diploid cells in the primitive endoderm
(Supplementary Fig. 4e).
As an alternative approach, we also generated double size
diploid–aneuploid mosaic chimeras (16-cell embryos) by aggre-
gating whole 8-cell diploid embryos with whole 8-cell aneuploid
embryos and culturing them in IVC medium after immunosur-
gery to isolate ICM (Supplementary Fig. 5a). In agreement with
the above results, we found that both double size diploid–diploid
chimeras and diploid–aneuploid chimeras developed the char-
acteristic post-implantation morphology at equivalent rates
(Supplementary Fig. 5b, c). These chimeras also showed a
significant reduction in the relative proportion of non-fluorescent
cells in the diploid (red)–aneuploid (non-fluorescent) chimeras
than in the diploid (red)–diploid (non-fluorescent) chimeras both
in the epiblast and the primitive endoderm (Supplementary
Fig. 5b, d–f). Specifically, the frequency of non-fluorescent
aneuploid cells in diploid–aneuploid epiblasts was 33.3%, while
the frequency of non-fluorescent diploid cells in diploid–diploid
epiblasts was 69% (Supplementary Fig. 5d). The frequency of
non-fluorescent aneuploid cells in diploid–aneuploid primitive
endoderm was 37.5%, while the frequency of non-fluorescent
diploid cells in diploid–diploid primitive endoderm was 74.9%
(Supplementary Fig. 5d). Strikingly, 53.3% of the diploid–
aneuploid epiblasts contained no non-fluorescent aneuploid cells.
In contrast, only 15.4% of the diploid–diploid epiblasts lacked
non-fluorescent diploid cells (Supplementary Fig. 5g). Further-
more, 23.3% of diploid–aneuploid chimeras contained no non-
fluorescent aneuploid cells in the primitive endoderm, whereas all
of the diploid–diploid chimeras contained non-fluorescent cells in
the primitive endoderm (Supplementary Fig. 5h). Consistently, in
the 16-cell double size chimeras in which the TE was not
removed, there was a significant reduction in the frequency of
aneuploid cells in the epiblast, but not in the primitive endoderm
(Supplementary Fig. 6a–e). Taken together, these results indicate
that aneuploid cells are preferentially eliminated during remodel-
ling of the epiblast, both in vitro and in vivo.
Aneuploid cell depletion from the epiblast by apoptosis. Since
our results indicated a significant elimination of the aneuploid
cells from the epiblast, we next decided to focus on this lineage
and wished to determine how the aneuploid cells become elimi-
nated from diploid–aneuploid mosaic embryos during epiblast
morphogenesis after implantation. To follow the behaviour and
survival of aneuploid cells, we generated chimeric embryos in
which aneuploid clones were distinguished by their expression of
green nuclear (histone H2B-GFP) and diploid cells of red
membrane (mT/mG) fluorescent markers, isolated ICMs by
immunosurgery, embedded them in Matrigel and IVC medium
and carried out time-lapse imaging under a spinning disc con-
focal microscope for 72 h (Fig. 2a). Our live embryo imaging
revealed several morphological features characteristic of apopto-
sis18 in the green fluorescent aneuploid cells. This included
nuclear condensation, followed by the formation of the apoptotic
bodies and subsequent removal of the cellular debris (Fig. 2a,
Supplementary Movie 1). We found that double size
diploid–aneuploid chimeras also displayed similar features indi-
cative of apoptosis of the aneuploid cells in the epiblast and
engulfment of the apoptotic bodies by the neighbouring red
fluorescent control cells (Fig. 2b, Supplementary Movie 2). We
also observed apoptosis of the aneuploid cells in the post-
implantation epiblasts of diploid–aneuploid chimeras in which
the TE was not removed and which developed through implan-
tation in vivo (Fig. 2c, Supplementary Movie 3). These observa-
tions suggest that aneuploid cells are preferentially depleted from
the epiblast by apoptosis and the apoptotic debris was gradually
cleared from the embryo during the peri-implantation stages of
development both in vivo and in vitro.
Size regulation of diploid–aneuploid mosaic epiblasts. In order
to determine the effect of preferential elimination of aneuploid
epiblast cells from diploid–aneuploid embryos on the overall
mosaic embryo development, we next analysed the mosaic epi-
blast at the end of peri-implantation development in greater
detail. Strikingly, we found that despite the depletion of aneuploid
cells from the diploid (red)–aneuploid chimera epiblast,
diploid–diploid and diploid–aneuploid epiblasts had a similar
average cell number after 72 h of IVC culture (Fig. 3a). Both
double size diploid–diploid chimeras and diploid–aneuploid
chimeras also contained an equivalent number of cells in the
epiblast after 72 h of IVC culture (Fig. 3b). The average number
of cells in the early post-implantation epiblast was also similar in
diploid–diploid and diploid–aneuploid chimeras (Fig. 3c), as well
as in double size chimeras (Supplementary Fig. 6f) in which the
TE was not removed and which were allowed to implant in vivo.
These results suggested the possibility of compensatory pro-
liferation of diploid cells to regulate the total number of epiblast
cells.
To assess cell proliferation in the epiblasts, we generated again
mosaic aneuploid–diploid and diploid–diploid chimeras, as above
(Fig. 1a), cultured them in vitro in IVC medium and analysed the
frequency of cells displaying the mitotic marker, phosphorylated
histone H319. We found that the red fluorescent, diploid
clone showed a higher mitotic index in the diploid (red)–
aneuploid epiblast than in the diploid (red)–diploid epiblast
Fig. 1 Aneuploid cells become eliminated during peri-implantation epiblast remodelling. Embryos were treated with reversine (or DMSO) at the four- to
eight-cell stage transition and eight-cell chimeras containing a 1:1 ratio of control (diploid) and reversine-treated (aneuploid) cells were constructed from
mT/mG (red) diploid cells and non-fluorescent aneuploid cells at the eight-cell stage. a At the late blastocyst stage, immunosurgery was performed to
isolate the inner cell mass (ICM) from the trophectoderm (TE). Chimeras were embedded in Matrigel and cultured in IVC medium for 72 h to allow
development into an epithelised epiblast (EPI) surrounded by a primitive endoderm (PE) layer with a central lumen. b In these examples, the diploid–diploid
EPI contains both red fluorescent and non-fluorescent cells. Whereas, the majority of the diploid–aneuploid chimera originates from the red fluorescent
diploid clone. Scale bars, 30 μm. c After culture according to (a), average distribution of red fluorescent and non-fluorescent cells was assessed for both
types of chimeras in the EPI and PE. For b and c, diploid–diploid n= 21 embryos; n= 2636 EPI cells; n= 3003 PE cells and diploid–aneuploid n= 19
embryos; n= 1900 EPI cells; n= 2306 PE cells. d At the early blastocyst stage, chimeras were transferred to pseudo-pregnant mothers and recovered 12 h
after implantation and cultured in IVC medium for 36 h. e In these examples, the diploid–diploid EPI contains both red fluorescent and non-fluorescent cells.
Whereas, most of the diploid–aneuploid chimera EPI originated from the red fluorescent diploid clone. Scale bars, 40 μm. Squares indicate magnified
regions. Scale bars, 20 μm. f After culture according to (d), average distribution of red fluorescent and non-fluorescent cells was assessed for both types of
chimeras in the EPI and PE. For the EPI (f), diploid–diploid n= 7 embryos; n= 807 EPI cells and diploid–aneuploid n= 14 embryos; n= 1640 EPI cells. For
(e) and the PE (f), diploid–diploid n= 6 embryos; n= 1110 PE cells and diploid–aneuploid n= 8 embryos; n= 1488 PE cells. Source data are provided as a
Source Data file.
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during the peri-implantation stage of development (Fig. 3d).
These results indicate increased proliferation of the diploid cells
in the presence of aneuploid cells, compensating for the loss of
aneuploid cells in the diploid–aneuploid mosaic epiblast, thus
allowing for the maintenance of a similar number of cells as
found in diploid–diploid epiblasts.
Autophagy is required for aneuploid cell elimination. Since our
results above together with our previous report14, indicate that
the aneuploid cells become eliminated during late pre- and peri-
implantation developmental stages, we sought to investigate the
mechanism triggering this process in more detail. We first wished
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cells as the pre-implantation development progresses. To this end,
we generated aneuploid embryos, by reversine treatment at the
four- to eight-cell stage as before, and cultured aneuploid and
diploid control embryos in the presence of the pan-caspase
inhibitor ZVAD, which prevents apoptosis20. We imaged devel-
opment of embryos in the presence of SYTOX21, which allowed
us to detect cell death in live embryos during blastocyst
maturation (Supplementary Fig. 7a, Supplementary Movie 4). We
found that ZVAD treatment reduced the number of dying cells in
the aneuploid embryos (Supplementary Fig. 7b). Consequently,
the reduction in the epiblast cell number in aneuploid late blas-
tocysts compared to diploid late blastocysts, was alleviated after
ZVAD treatment (Supplementary Fig. 7c).
It has been shown that gene imbalances caused by aneuploidy
can lead to proteomic imbalances22–24. We have therefore next
set out to investigate whether aneuploid embryos display
proteotoxic stress. As the heat shock protein 70 (HSP70) are a
group of molecular chaperones instrumental in alleviating
Fig. 2 Elimination of aneuploid epiblast cells during peri-implantation development by apoptosis. Chimeras containing a 1:1 ratio of control (diploid) and
reversine-treated (aneuploid) cells were constructed from mT/mG (red) diploid cells and Histone H2B-GFP (green) aneuploid cells at the eight-cell stage
and cultured beyond the blastocyst stage. Sequential representative images from time-lapse series for three diploid–aneuploid chimeras are shown, each
showing apoptosis of an aneuploid cell (histone H2B-GFP) (white boxes) during pre- to post-implantation development. White arrows indicate the
apoptotic debris. a Eight-cell diploid–aneuploid chimeras (n= 12 embryos) were generated at the eight-cell stage. Immunosurgery was performed at the
late blastocyst stage to isolate the ICM from the TE. The ICMs were embedded in Matrigel and cultured in IVC medium for 72 h, during which they were
live-imaged. Scale bar, 20 μm. Squares indicate magnified regions. Scale bar, 7 μm. Three z-planes have been shown. b Sixteen-cell diploid–aneuploid
chimeras (n= 22 embryos) were generated at the eight-cell stage. Immunosurgery was performed at the late blastocyst stage and ICMs were cultured in
IVC medium for 72 h, during which they were live-imaged. Scale bar, 20 μm. Squares indicate magnified regions. Scale bar, 7 μm. Three z-planes have been
shown. c Eight-cell diploid–aneuploid chimeras (n= 12 embryos) were generated at the eight-cell stage. At the early blastocyst stage, the chimeras were
transferred to pseudo-pregnant mothers and recovered 12 h after implantation to be cultured in vitro for 36 h and live-imaged. Scale bar, 40 μm. Squares
indicate magnified regions. Scale bar, 10 μm.
a b c
d
Fig. 3 Size regulation of diploid–aneuploid epiblasts during peri-implantation development. Embryos were treated with reversine (or DMSO) at the four-
to eight-cell stage transition. a Eight-cell diploid–aneuploid and diploid–diploid chimeras were generated at the eight-cell stage. Immunosurgery was
performed at the late blastocyst stage to isolate the ICM from the TE. The ICMs were embedded in Matrigel and cultured in IVC medium for 72 h. n= 19
diploid–aneuploid; n= 1900 EPI cells and n= 21 diploid–diploid chimeras; n= 2636 EPI cells. Student’s t test. b Sixteen-cell diploid–aneuploid and
diploid–diploid chimeras were generated at the eight-cell stage. Immunosurgery was performed on the double size chimeras and ICMs were cultured in IVC
medium for 72 h as above. Diploid–diploid n= 26 chimeras; n= 1772 EPI cells and diploid–aneuploid n= 30 chimeras; n= 1961 EPI cells. Mann–Whitney
test. c Eight-cell diploid–aneuploid and diploid–diploid chimeras were transferred to pseudo-pregnant mothers and recovered 12 h after implantation and
then in vitro cultured for 36 h. n= 4 diploid–aneuploid; n= 604 EPI cells and n= 6 diploid–diploid chimeras; n= 737 EPI cells. Mann–Whitney test. For
graphs a–c, relative number of cells in the EPI were analysed for both types of chimeras (relative to the average of diploid–diploid chimeras) at the end of
the peri-implantation culture to investigate the level of size regulation of diploid–aneuploids with respect to diploid–diploids. ns= not significantly different.
d Eight-cell diploid (red)–aneuploid and diploid (red)–diploid chimeras were generated. Immunosurgery was performed and ICMs were cultured as above
for 48 h. The percentage of the number of pH3-positive red fluorescent EPI cells of the total red fluorescent EPI cells was analysed for each chimera, for
both diploid–diploid and diploid–aneuploid ICMs. n= 21 diploid–aneuploid; n= 546 red EPI cells and n= 13 diploid–diploid chimeras; n= 217 red EPI cells.
Scale bars, 20 μm. Squares indicate magnified regions. Scale bars, 10 μm. Student’s t test and **p= 0.0084. For all the graphs, all data are mean ± s.e.m.
Source data are provided as a Source Data file.
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misfolded protein stress25, we compared HSP70 levels between
diploid (control) and aneuploid (reversine-treated) embryos. We
found that aneuploid embryos displayed higher HSP70 levels
than diploid embryos from the eight-cell stage through to the late
blastocyst stage (Fig. 4a), indicative of chronic misfolding. HSP70
levels in the epiblast of aneuploid late blastocysts were also
significantly higher than in diploid blastocysts (Supplementary
Fig. 8a).
The cell responds to an increase in misfolded proteins by
upregulating protein quality control mechanisms such as autop-
hagy26. Therefore, we hypothesised that autophagy might be
upregulated in aneuploid embryos in response to this proteotoxic
stress. During autophagy, the autophagosome forms around cargo
and fuses with lysosomes, leading to degradation of the cargo27. The
microtubule-associated light-chain 3B (LC3B) and p62/sequesto-
some 1 (SQSTM1) proteins are associated with the autophagosome
membrane and accumulate during autophagy27. They are the two
widely used markers of autophagy28. Firstly, to investigate if
proteotoxic stress can lead to the upregulation of autophagy, we
treated embryos with 5 μM MG132, the proteasome inhibitor29, for
6 h. We observed a significant increase in the LC3B accumulation in
the MG132-treated epiblast compared to the control epiblast at the
late blastocyst stage (Fig. 4b). To investigate the same in aneuploid
cells, LC3B and p62 levels were analysed in the epiblast of aneuploid
blastocysts. We observed a significant increase in the number of
LC3B (Fig. 4c) and p62 (Fig. 4d) puncta in the epiblast of aneuploid
blastocysts compared to diploid blastocysts. These increases in
LC3B and p62 puncta in the aneuploid blastocysts compared to
controls were at least in part due to increased levels of their
respective transcripts (Supplementary Fig. 8b). As an alternative
method to reversine, we also wished to inhibit the SAC by targeting





Fig. 4 Chronic protein misfolding and autophagy upregulation in the aneuploid EPI cells. a HSP70 immunostaining in diploid and aneuploid embryos at
indicated stages. Scale bars, 20 μm. Control diploid embryos: 8-cell n= 12, morula n= 9, early blastocyst n= 9, late blastocyst n= 14. Reversine-treated
aneuploid embryos: 8-cell n= 10, morula n= 9, early blastocyst n= 9, late blastocyst n= 18. b Embryos were treated with MG132 (or DMSO) at the late
blastocyst stage for 6 h and immunostained for LC3B. Each dot represents the average number of LC3B puncta/cell in an embryo. Mann–Whitney test.
Control n= 5, MG132-treated n= 8 embryos. Scale bars, 20 μm. Squares indicate the magnified regions. Scale bars, 10 μm. *p= 0.0295. Analysis of LC3B
(c) and p62 (d) immunostaining in diploid and aneuploid late blastocysts’ EPI. Each dot represents the average number of LC3B (c) or p62 (d) puncta/cell
in an embryo. Scale bars, 20 μm. Squares indicate magnified regions. Scale bar, 5 μm. For c, diploid n= 16 embryos and aneuploid n= 17 embryos.
Student’s t test, **p= 0.0059. For d, diploid n= 18 embryos and aneuploid n= 18 embryos. Student’s t test, **p= 0.0033. e Zygotes were injected with
dsGFP (control) or dsMad2 and immunostained for LC3B at the late blastocyst stage. Each dot represents the average number of LC3B puncta/cell in an
embryo. Student’s t test with Welch’s correction, *p= 0.0106. dsGFP n= 11, dsMad2 n= 12 embryos. Scale bars, 20 μm. Squares indicate the magnified
regions. Scale bars, 10 μm. For graphs b–e, data are shown as individual data points in a Box and Whiskers graph (bottom: 25%; top: 75%; line: median;
whiskers: min to max). Source data are provided as a Source Data file.
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upregulation of autophagy observed in reversine-treated epiblast
cells could be an off-target effect of reversine. To this end, we
injected zygotes with dsRNA targeting GFP (dsGFP), as a control,
or Mad2 (dsMad2) and analysed LC3B accumulation at the
blastocyst stage. We confirmed that injection of dsMad2 reduced
Mad2 mRNA to 15% relative to embryos injected with dsGFP
(Supplementary Fig. 8c). We found that dsRNA-mediated depletion
of Mad2 also led to significant increase in the LC3B accumulation
in the epiblast (Fig. 4e). Overall, these results suggest that aneuploid
epiblast cells upregulate autophagy at the blastocyst stage.
To investigate the possible role of autophagy in aneuploid
embryos, we used the lysosomal inhibitor Bafilomycin A128
(BafA1) or RNAi-mediated depletion of the essential autophagy
factor Atg530 to disrupt autophagy. We treated aneuploid and
diploid embryos with 160.6 nM BafA1 and imaged them in the
presence of SYTOX to detect dying cells from the early to the late
blastocyst stage. We found that BafA1 treatment reduced the
number of dying cells in the ICM of aneuploid, but not diploid,
embryos (Fig. 5a). Similarly, we injected two-cell stage embryos
with Atg5 siRNA, treated them with reversine or DMSO at the
four- to eight-cell stage and imaged them in the presence of
SYTOX from the early blastocyst to the late blastocyst stage. We
confirmed that injection of Atg5 siRNA reduced Atg5 mRNA to
23% relative to embryos injected with control siRNA (Supple-
mentary Fig. 8d). RNAi-mediated depletion of Atg5 also reduced
the number of dying cells in the ICM of aneuploid, but not
diploid, embryos (Fig. 5b). To further confirm the role of
autophagy in the elimination of aneuploid cells, we treated
embryos with rapamycin31, which induces autophagy. We found
that rapamycin treatment did not affect the number of dying cells
in the ICM of either aneuploid or diploid embryos (Fig. 5c).
Interestingly, rapamycin treatment did not increase the number
of dying cells in the ICM of aneuploid embryos. This could be
because the elimination of aneuploid cells from the mouse
epiblast may not be dependent on the mTOR-autophagy pathway
or alternatively, autophagy may be required but might not be
sufficient to eliminate aneuploid cells. Future studies might be
able to distinguish between these possibilities. Taken together our
results suggest that autophagy is required to eliminate aneuploid




Fig. 5 Autophagy upregulation mediates cell death in the ICM of aneuploid pre-implantation embryos. a Diploid and aneuploid embryos were imaged
with Bafilomycin A1 (BafA1) or DMSO and SYTOX from the early to late blastocyst stage (24 h). The number of dying ICM cells was assessed relative to
the average number of dying cells in DMSO-treated diploid ICMs. Diploid n= 26 embryos, aneuploid n= 24 embryos, diploid BafA1 n= 23 embryos,
aneuploid BafA1 n= 24 embryos. Kruskal–Wallis test, *p= 0.0435, **p= 0.0050. b Two-cell stage embryos were injected with Atg5 siRNA or control
siRNA, treated at the four- to eight-cell stage with reversine or DMSO, and imaged with SYTOX during blastocyst maturation (24 h). The number of dying
ICM cells was assessed relative to the average number of dying cells in control siRNA-injected diploid ICMs. Diploid n= 20 embryos, aneuploid n= 21
embryos, diploid Atg5 siRNA n= 21 embryos, aneuploid Atg5 siRNA n= 27 embryos. One-way ANOVA test, *p= 0.0374, **p= 0.0068. c Diploid
(DMSO-treated) and aneuploid (reversine-treated) embryos were treated with DMSO or rapamycin (Rapa) from the early to the late blastocyst stage
(24 h) and imaged in the presence of SYTOX to label dying cells. Diploid n= 15 embryos, aneuploid n= 12 embryos, diploid rapa n= 15 embryos, aneuploid
rapa n= 15 embryos. One-way ANOVA test, *p= 0.0358. For all the graphs, data are shown as individual data points in a Box and Whiskers graph
(bottom: 25%; top: 75%; line: median; whiskers: min to max), ns not significantly different. Source data are provided as a Source Data file.
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We next sought to investigate whether the elimination of
aneuploid cells in peri-implantation embryos is triggered by the
same molecular cascade as at the blastocyst stage. To this end, we
treated embryos with reversine (or DMSO for control) at the four-
to eight-cell stage transition, as before, performed immunosurgery
to remove the TE, and cultured the ICMs for 48 h in IVC medium
in Matrigel. We observed an increase in LC3B puncta in aneuploid
embryos compared to diploid embryos, suggesting that autophagy
is increased as the aneuploid ICM develops beyond the blastocyst
stage (Fig. 6a).
To investigate the functional significance of autophagy in the
elimination of aneuploid cells, we cultured aneuploid embryos in
the presence of BafA1 from the early blastocyst to the late
blastocyst stage, performed immunosurgery to isolate the ICMs,
and cultured the ICMs in the presence of BafA1 for a further 72 h




Fig. 6 Autophagy upregulation mediates cell death in the ICM of aneuploid peri-implantation embryos. a Embryos were treated at the four- to eight-cell
stage with reversine or DMSO. Control (diploid) and reversine-treated (aneuploid). After immunosurgery at the late blastocyst stage, ICMs were
embedded in Matrigel and cultured in IVC medium. LC3B immunostaining was analysed in diploid and aneuploid EPIs after 48 h IVC in vitro culture. Each
dot represents the average number of LC3B puncta/cell in each EPI. Scale bars, 7 μm. Squares indicate magnified regions. Scale bars, 2 μm. Mann–Whitney
test, *p= 0.0409. Diploid n= 25 embryos and aneuploid n= 18 embryos. Data are shown as individual data points in a Box and Whiskers graph (bottom:
25%; top: 75%; line: median; whiskers: min to max). b Embryos were treated at the four- to eight-cell stage with reversine or DMSO. Diploid and aneuploid
embryos were cultured in DMSO or BafA1 during blastocyst maturation. Immunosurgery was performed and ICMs were cultured as above for 72 h in
DMSO or BafA1. c Diploid and aneuploid ICMs were cultured as shown in (b) for 72 h and analysed for the efficiency of formation of an organised structure
comprising an epithelised EPI surrounded by a PE layer with a central lumen. Scale bars, 30 µm. d Relative (to diploids) efficiency of ICMs in forming an
organised structure, assessed according to (c), was evaluated. n= 3 independent experimental groups. Diploid n= 34 embryos, aneuploid n= 36 embryos
and aneuploid BafA1= 31 embryos. e Relative (to diploids) number of cells in the EPI was analysed for organised structures obtained in (c) for all three
conditions. One-way ANOVA test, *p= 0.0450. For c and e, diploid n= 18 embryos; n= 1246 EPI cells, aneuploid n= 10 embryos; n= 352 EPI cells and
Aneuploid BafA1= 9 embryos; n= 563 EPI cells. For graphs d and e, all data are mean ± s.e.m. For all the graphs, ns not significantly different. Source data
are provided as a Source Data file.
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increase in the number of epiblast cells and allowed more
embryos to form organised structures in which the primitive
endoderm surrounded an epiblast which underwent lumenogen-
esis (Fig. 6c–e). Consequently, the size of the epiblast of diploid
and autophagy-inhibited aneuploid rosette structures were
equivalent (Fig. 6c, e), suggesting that autophagy is involved in
elimination of aneuploid cells that otherwise would have
contributed to development.
To confirm whether autophagy indeed led to the elimination of
aneuploid cells, we again cultured reversine-treated embryos with
(or without as controls) BafA1 from the early blastocyst stage to
the early post-implantation stage and examined their chromoso-
mal integrity by performing metaphase spreads. This revealed
that while reversine-treated embryos without autophagy inhibi-
tion were mostly diploid, the reversine-treated embryos after
autophagy inhibition were mostly aneuploid (Supplementary
Fig. 8e). Taken together our results suggest that autophagy
eliminates aneuploid cells at both the pre- and peri-implantation
stages of development.
p53 activation induces autophagy-mediated cell elimination.
Aneuploidy arises from chromosome missegregation. Studies of
human cells and mouse embryos have shown that chromosome
missegregation is followed by p53 activation, and that p53 limits
the proliferation of aneuploid cells32–34. To test if the induction of
aneuploidy induces a similar p53 response in the mouse embryo,
we treated embryos with reversine (or DMSO) at the four- to
eight-cell stage, as previously, and examined the mRNA levels of
p53 and three p53-responsive genes35, the cyclin-dependent
kinase inhibitor p21, cyclin G1 and bcl-2. We observed an
increase in the mRNA levels of p53, p21 and cyclin G1, and a
decrease in bcl-2 mRNA levels, in aneuploid blastocysts compared
to diploid blastocysts, indicating an upregulation of the p53
pathway (Fig. 7a). As a positive control, embryos were treated with
Nutlin-336, a p53-activating drug (or DMSO) from the late eight-
cell stage until the late blastocyst stage and examined for cyclin G1
mRNA levels. We observed an increase in cyclin G1 mRNA levels
in Nutlin-3 treated blastocysts compared to control blastocysts
(Supplementary Fig. 9a).
To investigate the functional significance of p53 in the
elimination of aneuploid cells, we used RNAi to deplete p53.
p53 siRNA injection reduced p53 mRNA to 16% and cyclin G1
mRNA to 6.3% relative to embryos injected with control siRNA
(Supplementary Fig. 9b). We injected both blastomeres at the
two-cell stage with p53 siRNA, treated embryos with reversine or
DMSO at the four- to eight-cell stage and imaged in the presence
of SYTOX to detect dying cells. We found that p53 depletion
reduced the number of dying cells in the ICM of aneuploid
embryos (Fig. 7b), suggesting that the p53 pathway mediates the
removal of aneuploid cells. Since p53 depletion also reduced the
number of dying cells in the ICM of diploid embryos, this
indicates that the elimination of cells by p53 pathway is not
specific to the induction of chromosomal abnormality.
Since our results indicate that both the p53 pathway and
autophagy are required to eliminate aneuploid cells from the ICM
during blastocyst maturation (Figs. 5 and 7b), we finally sought to
determine if the p53 pathway is required to induce autophagy in
aneuploid cells. To this end, we injected both blastomeres at the
two-cell stage with p53 siRNA, treated embryos with reversine (or
DMSO) at the four- to eight-cell stage and analysed LC3B
accumulation upon p53 depletion in aneuploid pre-implantation
embryos. We found that depletion of p53 reduced the number of
LC3B puncta/cell in the epiblast of aneuploid blastocysts, but not
diploid blastocysts (Fig. 7c). In contrast, depletion of Atg5 by
siRNA did not affect the mRNA levels of p53 in aneuploid
blastocysts, indicating that aneuploidy-induced activation of p53
does not result from autophagy upregulation (Supplementary
Fig. 10). Overall, these results indicate that the aneuploidy-induced
accumulation of LC3B results from p53 activation. Together, our
findings suggest that the p53 pathway induces autophagy-mediated
elimination of aneuploid cells from the mouse epiblast and we
propose that the chronic misfolded protein stress stimulates the
p53 pathway in such cells (Fig. 7d).
Discussion
In this study, we have made three principle discoveries: first, that
aneuploid cells are preferentially eliminated by apoptosis during
epiblast remodelling at the peri- and early post-implantation
stages of development and therefore prior to gastrulation; second,
that p53-induced autophagy is required to eliminate aneuploid
cells and third, that normal diploid cells increase their pro-
liferation rate to compensate for aneuploid cell elimination to
regulate embryo size.
The preferential depletion of aneuploid cells from the epiblast
via apoptosis throughout the peri-implantation and early post-
implantation stages of development that we report here (Fig. 8a),
suggests that the progressive clonal depletion of aneuploid cells
might ensure the survival of healthy mosaic embryos12,13. This
study directly demonstrates the progressive depletion of aneu-
ploid cells by apoptosis during peri-implantation and early
post-implantation embryogenesis. As distinct aneuploidies show
different levels of proliferative disadvantage37,38, this could
account for the variation we see in the timing and extent of the
depletion of aneuploid cells, thereby influencing the epiblast cell
number and overall developmental success, as it has been shown
that the successful post-implantation development correlates with
the number of cells in the epiblast39.
Despite the depletion of aneuploid cells as development pro-
gresses, we have found that diploid–aneuploid mosaic epiblasts
have a similar size to diploid epiblasts by the early post-
implantation stage. Since we find that diploid cells within mosaic
epiblasts increase their proliferation rate, our results suggest that
diploid cells compensate for the loss of aneuploid cells and in this
way can regulate the size of the epiblast. This observation is in
accord with reports showing that half-size embryos, made by
separating blastomeres at the two-cell stage, can undergo com-
pensatory proliferation to increase their size40. Although the
mechanisms of size regulation remain unknown, this embryo
plasticity is fundamental to tissue integrity and function.
To explore the relationship between aneuploidy and apoptosis,
we compared the development of aneuploid and control embryos.
Studies in diverse organisms indicate that overall gene expression
and translation levels correlate with gene copy number in aneu-
ploid cells41–46. Aneuploidy perturbs the normal stoichiometry of
protein complex subunits, leading to intracellular proteomic
imbalance47. Interestingly, aneuploidies of differing chromo-
somes have been reported to show common cellular responses
including the downregulation of proliferation-related genes, the
upregulation of energy metabolism and an increased sensitivity to
conditions interfering with protein folding41,48,49. It has been
shown in human cells that a persistent aneuploid karyotype, as in
our case, is required to promote autophagy50. Here, we see a
similar response and a significant upregulation of autophagy in
the epiblast of aneuploid embryos.
To examine the involvement of autophagy in facilitating the
elimination of aneuploid cells, we inhibited the process at two
different stages: autophagosome formation by depleting Atg5 and
lysosome fusion by treating with Bafilomycin A1. Both treatments
attenuated cell death in the ICM of aneuploid embryos from the
early to the late blastocyst stages suggesting that the entire
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autophagic flux is required. Inhibition of autophagy did not affect
the level of cell death in untreated control embryos, consistent
with the studies showing that autophagy is not involved in pro-
grammed cell death during embryo development51,52. While
autophagy generally has pro-survival functions in a cell, it can
occasionally lead to cell death53. The mechanisms that link
autophagy and apoptosis are not clear but there are several
potential routes through which autophagy could lead to apop-
tosis. Firstly, p62 could activate caspase-8 leading to further
activation of apoptotic machinery. Secondly, autophagy might
degrade cellular components leading the cell to eventually activate
the apoptotic machinery. Finally, autophagy could specifically
degrade apoptotic machinery components (such as mitochondria)
thereby lowering the pro-apoptotic activity threshold and acti-
vating apoptosis faster53. Since we observed that rapamycin
treatment did not increase the number of dying cells in the
aneuploid ICM, it will be interesting to explore in the future
whether autophagy activates apoptotic machinery in aneuploid
epiblast cells indirectly.
Our results also demonstrate that the p53-autophagy cascade
contributes to the removal of aneuploid cells from the epiblast as
we find that p53 depletion attenuates cell death in the ICM of
aneuploid embryos during blastocyst maturation. We also show




Fig. 7 p53-induced autophagy in the ICM of aneuploid pre-implantation embryos. a Embryos were treated at the four- to eight-cell stage with DMSO
(diploid) or reversine (aneuploid) and mRNA expression for genes involved in p53 pathway were assessed at the late blastocyst stage (relative to diploid
embryos) using qRT-PCR. Diploid n= 69 embryos, aneuploid n= 67 embryos. Mann–Whitney test, *p= 0.0286. All data are mean ± s.e.m. b Two-cell
stage embryos were injected with p53 siRNA or control siRNA, treated from four- to eight-cell stage with reversine or DMSO, and imaged in the presence
of SYTOX during blastocyst maturation (24 h). The number of dying cells in the ICM was assessed relative to the average number of dying cells in the ICM
in control siRNA-injected diploids. Diploid n= 20 embryos, aneuploid n= 20 embryos, diploid p53 siRNA n= 19 embryos, aneuploid p53 siRNA n= 18
embryos. One-way ANOVA test, *p= 0.0376 (diploid versus aneuploid), 0.0476 (diploid vs. diploid p53 siRNA), 0.0158 (aneuploid vs. aneuploid
p53 siRNA). c Two-cell stage embryos were injected with p53 siRNA or control siRNA, treated at the four- to eight-cell stage with reversine or DMSO. The
level of autophagy (average LC3B puncta/cell in an embryo) in the EPI was assessed at the late blastocyst stage using immunostaining. Diploid n= 19
embryos, aneuploid n= 18 embryos, Diploid p53 siRNA n= 11 embryos, aneuploid p53 siRNA n= 12 embryos. Scale bar, 10 μm. One-way ANOVA test,
**p= 0.0055, *p= 0.0149. For the graphs b and c, data are shown as individual data points in a Box and Whiskers graph (bottom: 25%; top: 75%; line:
median; whiskers: min to max). For all the graphs, ns = not significantly different, *p < 0.05 and **p < 0.01. d Schematic of the events downstream of
aneuploidy in mouse embryos, leading to programmed cell death of the cell. Source data are provided as a Source Data file.
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the epiblast of aneuploid embryos. However, the mechanisms
which upregulate the p53 pathway in aneuploid embryos are not
clear. In both yeast and mammalian cells, the bcl-2 anti-apoptotic
protein can also function to prevent autophagy54. In accordance
with this, we observe downregulation in the levels of bcl-2 in
aneuploid embryos. In the future, it will be interesting to explore
whether reduced levels of bcl-2 directly upregulate autophagy in
aneuploid cells to mediate apoptosis.
This study establishes a direct link between autophagy and
apoptosis in development of aneuploid embryos. Furthermore,
this study provides direct evidence that autophagy in the epiblast
can be utilised as a defence mechanism to deplete abnormal cells
during late pre-, peri and early post-implantation development.
While we expected aneuploid embryos to be eliminated at the
early post-implantation stage, we saw a high incidence of aneu-
ploidy in viable early post-implantation embryos when autophagy
was inhibited. This indicates that if autophagy is defective or if it
does not effectively deplete aneuploid cells, these cells would
contribute to the subsequent embryo morphogenesis, with det-
rimental effect upon embryo survival to birth. In this study we
determined the effect of global aneuploidy on cell and embryo
morphogenesis. Recently it was shown that tetraploid embryonic
stem cells (ESCs) undergo apoptotic elimination from the mouse
ESC–embryo chimeras via mTOR, when surrounded by diploid
cells20. However, tetraploidy and single-chromosome aneuploidy
could exhibit different physiological responses in a cell since
tetraploidy quadruples the entire genome without affecting
the relative stoichiometry of proteins, and therefore similar
mechanisms might not apply to cell elimination in the model that
we present here. A better understanding of the phenotypic effects
of specific chromosomal abnormalities will help in future studies
to further illuminate the cellular processes affected by aneuploidy.
It will also be of future interest to explore whether similar
mechanisms extend to human embryos and thereby further
increase our understanding of early pregnancy loss.
Methods
Pre-implantation embryo culture and time-lapse imaging. This research has
been carried out following regulations of the Animals (Scientific Procedures)
Act 1986—Amendment Regulations 2012—reviewed by the University of
a
b
Fig. 8 Model for the elimination of aneuploid cells in the mouse embryo. a Aneuploid cells generated at the four- to eight-cell stage are progressively
depleted from the epiblast of the mosaic embryo from the early blastocyst stage to the early post-implantation via apoptosis. Diploid cells in the same
embryo over-proliferate to compensate for the reduction in overall epiblast cell number thereby allowing for successful development. b In a normal
(diploid) cell, cellular protein quality control mechanisms, involving the proteasome machinery and autophagy, degrade misfolded/unfolded proteins to
prevent cytotoxicity and promote healthy cell survival26. We hypothesise that in an aneuploid cell in the epiblast, gene aberrations are translated into
protein aberrations. Chronic protein misfolding after several mitotic divisions upregulates autophagy to an extent where instead of protecting the cell, it
mediates cell death. This prevents the aneuploid cell from continuing further in the development of the epiblast.
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Cambridge Animal Welfare and Ethical Review Body (AWERB). Animals were
maintained in the Animal Facility at 12:12 light cycle and provided with food
and water ad libitum. 4- to 6-week-old F1 (C57Bl/6× CBA) females were
injected with 10 IU of pregnant mare’s serum gonadotrophin (PMSG, Intervet)
and, 48 h later, with 10 IU of human chorionic gonadotrophin (hCG, Intervet).
These super-ovulated mice were then mated with F1 (C57Bl/6× CBA) males or,
where indicated, with Histone H2B-GFP55 or mT/mG (express membrane-
targeted tandem dimer Tomato)56 males. Embryos were recovered in M2
medium supplemented with 4 mg ml−1 bovine serum albumin (BSA) and cul-
tured in drops of KSOM media (Millipore) under mineral oil (Biocare Europe)
in 37 °C and 5% CO2. Reversine (Cayman Chemicals), Z-VAD-FMK (Enzo Life
Sciences), Bafilomycin A1 (Sigma-Aldrich), Nutlin-3 (Cayman Chemicals),
MG132 (Sigma-Aldrich) and Rapamycin (Millipore) were dissolved in dime-
thylsulfoxide (DMSO) (Sigma-Aldrich). They were respectively used at fol-
lowing final concentrations: 0.5 μM, 20 μM, 160.6 nM, 5 μM, 5 μM and 400 nM.
Control embryos were incubated in the equivalent DMSO concentration.
Analysis of cell death in the embryo was carried out using 5 μM SYTOX Orange
nucleic acid stain (Life technologies). Embryos for live imaging were transferred
to glass-bottom dishes (MatTek) and cultured within the individual interstices
of a finely weaved nylon mesh (Plastok). Imaging was performed using a
spinning disk confocal microscopy system (3i Intelligent Imaging Innovations)
and SlideBook software. The images were captured every 10–20 min in 65 μm
stacks of 2.0–2.5 μm intervals.
Generation of chimeric embryos. The zona pellucida of 8-cell stage embryos was
removed by treatment with acidic Tyrode’s solution (Sigma-Aldrich). Two types of
mosaic chimeras were created at the eight-cell stage.
Single chimera: The embryos were incubated in Ca2+/Mg2+-free M2 for 5 min
and then disaggregated into individual blastomeres by gentle mouth pipetting. Four
control and four control/reversine-treated blastomeres were carefully aggregated
together in M2 to get an eight-cell chimera.
Double size chimera: A control and a control/reversine-treated embryo were
aggregated together in M2 to get a 16-cell chimera.
Peri-implantation embryo culture and time-lapse imaging. To culture embryos
through the pre- to post-implantation transition, the zona pellucida was removed
at the late blastocyst. Embryos/chimeras were exposed for 30 min to 20% rabbit
anti-mouse whole serum (Sigma-Aldrich) in M2 medium at 37 °C. Next, they were
incubated for 30 min with 20% guinea pig complement serum (Sigma-Aldrich) in
M2 medium at 37 °C. The damaged TE was removed by pipetting the embryos in
M2. ICMs were embedded in Matrigel. 20 μl drop of ice-cold growth factor-
reduced Matrigel (BD Biosciences) was placed in a well of a μ-Slide 8-well ibiTreat
(Ibidi) dish and embryos were mouth pipetted inside the Matrigel drop. The dish
was incubated for 5 min at 37 °C to allow the Matrigel to solidify. Then, 300 μl of
prewarmed IVC medium was added to the well.
Embryo imaging was performed using a spinning disk confocal at 37 °C and 5%
CO2. The images were captured every 20 min in 50–90 μm stacks of 2.5-μm
intervals.
IVC medium constitution: Advanced DMEM F12 (Thermo Fisher Scientific),
20% v/v heat-inactivated fetal bovine serum (FBS) (Stem Cell Institute), GlutaMAX
(Thermo Fisher Scientific), 25 Uml−1 penicillin—25 μg ml−1 streptomycin
(Thermo Fisher Scientific), 1× ITS-X (Thermo Fisher Scientific), 8 nM β-oestradiol
(Sigma-Aldrich), 200 ng ml−1 progesterone (Sigma-Aldrich) and 25 μM N-aceyl-L-
cysteine (Sigma-Aldrich).
Post-implantation recovery and time-lapse imaging. Chimeras at the blastocyst
stage were transferred into the uterine horn of pseudo-pregnant females that had
been mated with vasectomised males. Early post-implantation embryos were dis-
sected from the maternal decidua and recovered into M2 medium. For live ima-
ging, chimeras were transferred to glass-bottom dishes and cultured in drops of
prewarmed IVC medium under mineral oil for 36 h. Imaging was performed using
a spinning disk confocal microscopy system in 37 °C and 5% CO2. The images were
captured every 10 min in 70 μm stacks of 2.0-μm intervals.
dsRNA preparation. Mad2 dsRNA was designed to target a 300 bp region
encompassing the Mad2 siRNA sequence described in Bolton et al. (2016) and was
amplified from liver cDNA. In vitro transcription was performed using the
MEGAscript T7 transcription kit (Thermo Fisher Scientific) following the manu-




Microinjection. Microinjection was performed at the stage indicated using an
Eppendorf Femtojet Microinjector57. Embryos were placed in drops of M2 medium
covered by mineral oil during injection and transferred to pre-equilibrated KSOM
afterwards. Embryos were injected with 12 μM predesigned siRNAs (Qiagen) or
with AllStars Negative Control (Qiagen) siRNA for control. For each gene, three
oligos were supplied and mixed together in equal proportions. For dsRNA,
embryos were injected with 700 ng μl−1 dsRNA.





qRT-PCR. Blastocysts were collected for quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) 96 h later. Total RNA was extracted using
the Arcturus PicoPure RNA Isolation Kit and qRT-PCR was performed using
the Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies) and a Ste-
pOne Plus Real-time PCR machine (Applied Biosystems). The following pro-
gramme was used: 30 min 48 °C (reverse-transcription) followed by 10 min 95 °C
followed by 45 cycles of 15 s 95 °C (denaturing) and 1 min 60 °C (annealing and
extension). The ddCT method was used to determine relative levels of mRNA
expression, with gapdh as an endogenous control. Primers are in Supplementary
Table 1.
Immunofluorescence. Embryos were fixed in 4% PFA for 20 min at room tem-
perature. The embryos were permeabilised, washed in PBST (0.1% Tween 20
(Sigma-Aldrich) in phosphate-buffered saline (PBS)) and incubated in blocking
solution for 4 h at 4 °C and then with primary antibodies in blocking solution for
overnight at 4 °C. They were then washed in PBST and incubated with Alexa Fluor
secondary antibodies (Thermo Fisher Scientific, 1:400) in blocking solution for 1 h,
washed again and incubated with DAPI (Thermo Fisher Scientific) for 5 min.
Primary antibodies used: mouse anti-Cdx2 (Biogenex, 1:200), mouse anti-Oct3/4
(Santa Cruz Biotechnology, 5279, 1:200), goat Gata4 (Santa Cruz Biotechnology,
1237, 1:200), rat anti-Podocalyxin (R&D Systems, MAB1556, 1:500), rabbit anti-
RFP (Rockland, 600-401-379, 1:500), mouse anti-HSP70 (Proteintech, 66183, 1:50),
rabbit anti-p62 (Proteintech, 55274, 1:100), and rabbit anti-phospho-Histone H3
(Millipore, 06-570, 1:200). For primary antibody rabbit anti-LC3B (Cell Signalling,
2775, 1:200), embryos were fixed in 100% Methanol (Sigma-Aldrich) for 20 min at
−20 °C. Confocal imaging was carried out using Leica SP5 (LAS AF software)
inverted confocal microscope. Image files were viewed and analysed using ImageJ
software.
For pre-implantation embryos: Permeabilisation was for 20 min in 0.5% Triton
X-100 (Sigma-Aldrich) in PBS and blocking solution was 3% BSA (Sigma-Aldrich)
in PBST.
For peri- or post-implantation embryos/ICMs: Permeabilisation was for 15 min
in 0.3% Triton X-100 (Sigma-Aldrich) in PBS and blocking solution was 10% FBS
in PBST.
Metaphase spreads. Embryos were cultured in 0.1 µg ml−1 colcemid (Cayman
chemical) for 12 h to arrest them in metaphase. Hypotonic solution: 1% sodium
citrate (Sigma-Aldrich) and Carnoy’s fixative: 3:1 methanol: glacial acetic acid
(Sigma-Aldrich). Eight- to 16-cell embryos were incubated for 10 min in pre-
warm hypotonic solution and fixed for 30 min in Carnoy’s fixative. ICMs
embedded in Matrigel were incubated in Cell Recovery Solution (Corning) for
20 min at 4 °C and then taken out of Matrigel using pipetting. They were incu-
bated for 10 min in pre-warm hypotonic solution and fixed for 30 min in Car-
noy’s fixative.
Embryos were mouth pipetted on clean SuperFrost Plus Slide (Thermo Fisher
Scientific). Slides were air-dried and mounted with ProLong® Gold Antifade
Mountant with DAPI (Life Technologies). Spreads were analysed using Leica SP5
inverted confocal microscope.
Statistics. The statistical tests used are indicated in the corresponding figure
legends. In all cases, the two-tailed version of the test was used. Normality of
quantitative data was first assessed using D’Agostino’s K-squared test. Statistical
analysis was performed using Prism (GraphPad) software.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors claim that all relevant data of the findings in this work are provided within
the paper and Supplementary Information files. Raw data are provided in the Source
Data File.
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